TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12897561
Drug: Intravenous anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anesthesia with propofol 5 to 8 mg.kg‐1.h‐1 and remifentanil 10 to 30 microg.kg‐1.h‐1
Study: 12897561
Drug: Intravenous anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anesthesia with propofol-remifentanil
Study: 10581665
Drug: Emergency treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency treatment for acute exacerbations of obstructive pulmonary disease
Study: 22233697
Drug: Risperidone oral
Normalized name: risperidone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone oral solution (RIS-OS) plus clonazepam
Study: 22233697
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (RIS-OS plus clonazepam)
Study: 22233697
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments after 6-week treatment
Study: 14613759
Drug: Naringin (400mg/capsule/day)
Normalized name: Naringin
DrugBank: Naringin (DB16859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naringin (400mg/capsule/day) for 8 weeks
Study: 31793231
Drug: Intravenous rezafungin
Normalized name: Rezafungin
DrugBank: Rezafungin (DB16310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous rezafungin (600 mg and 1400 mg)
Study: 30616912
Drug: Nemonoxacin 500
Normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin 500 mg (NEMO-500MG)
Study: 30616912
Drug: Nemonoxacin 750
Normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin 750 mg (NEMO-750MG)
Study: 30616912
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg (LEVO)
Study: 21329501
Drug: Cognitive stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive stimulation therapy (CST) delivered to participants with mild AD and their companions together.
Study: 21329501
Drug: Cognitive stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive stimulation therapy (CST) delivered to companions of participants with mild AD alone.
Study: 21329501
Drug: Cognitive stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive stimulation therapy (CST) for participants with mild AD and their companions together.
Study: 21329501
Drug: Cognitive stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive stimulation therapy (CST) for companions of participants with mild AD alone.
Study: 20110015
Drug: Generic chlorphenesin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic chlorphenesin carbamate 250 mg
Study: 20110015
Drug: Generic chlorphenesin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic chlorphenesin carbamate 500 mg
Study: 20110015
Drug: Branded chlorphenesin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded chlorphenesin carbamate 250 mg
Study: 20110015
Drug: Branded chlorphenesin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded chlorphenesin carbamate 500 mg
Study: 15385380
Drug: Femoral nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoral nerve block with lidocaine 1.5% 15 mL (group FEM)
Study: 11118395
Drug: Intramuscular route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular route
Study: 17764789
Drug: Subcutaneous route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous route
Study: 9701523
Drug: Omeprazole therapy
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole therapy (duration: 80 months for hypergastrinaemia group, 55 months for control group)
Study: 8254816
Drug: RDA multivitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: RDA multivitamins plus 40,000 units vitamin A, 100 mg. vitamin B6, 2,000 mg. vitamin C, 400 units vitamin E and 90 mg. zinc
Study: 2572666
Drug: xamoterol 200
Normalized name: xamoterol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: xamoterol 200 mg b.i.d. for 4 weeks
Study: 1058527
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days pretreatment with 1‐asparaginase and prednisolone followed by a combination of rubidomycin and cytosine arabinoside (ARAP)
Study: 1058527
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with a combination of rubidomycin, cytosine arabinoside and prednisolone without 1‐asparaginase pretreatment (RAP)
Study: 8513841
Drug: Hydrocortisone 1%
Normalized name: HYDROCORTISONE 1% OINT
DrugBank: Hydrocortisone acetate (DB14539)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocortisone 1% cream
Study: 23352226
Drug: FF/VI 50/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/VI 50/25 μg
Study: 23332861
Drug: FF/VI 200/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/VI 200/25 μg
Study: 26059225
Drug: FF/VI 50/25-200/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/VI 50/25-200/25 μg
Study: 18452345
Drug: Quetiapine 300
Normalized name: quetiapine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 300 mg/day
Study: 18452345
Drug: Quetiapine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 600 mg/day
Study: 16702815
Drug: 9-aminocamptothecin (9-AC)
Normalized name: 9-aminocamptothecin
DrugBank: 9-aminocamptothecin (DB12515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-aminocamptothecin (9-AC) with CD formulation, 9.44 to 12.60 mg/m/cycle for 14 days
Study: 12620439
Drug: Transdermal E(2)
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal E(2) patch
Study: 12620439
Drug: Transdermal E(2)
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal E(2) gel
Study: 11762805
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (ciprofloxacin 750 mg plus roxithromycin 150 mg, bid. days 4-13)
Study: 9048239
Drug: Norethindrone acetate
Normalized name: Norethindrone Acetate
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norethindrone acetate (10 mg) with leuprolide acetate (1 mg)
Study: 9048239
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate (1 mg) alone
Study: 29605753
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group 2 - midwifery intervention plus dental intervention involving assessment/treatment from cost free local dental services
Study: 29605753
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - received oral health information at recruitment
Study: 25239521
Drug: nab-paclitaxel (135
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-paclitaxel (135 mg/m2, d1, 8, q3w) plus carboplatin (AUC 5, d1, q3w)
Study: 25239521
Drug: gemcitabine (1,250
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine (1,250 mg/m2, d1, 8, q3w) plus carboplatin (AUC 5, d1, q3w)
Study: 22246377
Drug: Exenatide (0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (0.12 pmol/kg/min) infusion for 6 hours
Study: 22246377
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion for 6 hours
Study: 571216
Drug: 25% salt‐poor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% salt‐poor human albumin (1.5 ml/kg)
Study: 571216
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl in water (normal saline) (7 ml/kg)
Study: 26051574
Drug: Prolotherapy (hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolotherapy (hypertonic dextrose injection)
Study: 21034693
Drug: citalopram +
Approvals — FDA: no, EMA: no, PMDA: no
Description: citalopram + pindolol (5 mg tid)
Study: 17416939
Drug: Timolol/dorzolamide combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol/dorzolamide combination therapy
Study: 14657813
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 16 to 32 mg/kg/d for 6 days
Study: 10609908
Drug: Nitroglycerin 1
Normalized name: nitroglycerin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin 1 mg/ml
Study: 2014087
Drug: Short-term cefoxitin
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term cefoxitin prophylaxis (3 doses)
Study: 2014087
Drug: Long-term cefoxitin
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term cefoxitin prophylaxis (12 doses)
Study: 7049077
Drug: Clofazimine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofazimine (200 mg daily for 5 days)
Study: 31116261
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day adjunctive minocycline for MDD
Study: 23154591
Drug: conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional therapy without ARB (control group)
Study: 21252014
Drug: BIOBYPASS (AdGVVEGF121.10NH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIOBYPASS (AdGVVEGF121.10NH) gene therapy
Study: 3933035
Drug: Fluphenazine enanthate
Normalized name: Fluphenazine Enanthate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine enanthate (25 mg)
Study: 3933035
Drug: Fluphenazine decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine decanoate (25 mg)
Study: 26426458
Drug: Apneic oxygenation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apneic oxygenation (15 L/min of 100% oxygen via high-flow nasal cannula during laryngoscopy)
Study: 21406601
Drug: lisinopril 10
Normalized name: lisinopril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril 10 to 20 mg/d
Study: 21406601
Drug: lisinopril 10
Normalized name: lisinopril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril 10 to 20 mg/d plus simvastatin 20 mg/d
Study: 12074203
Drug: Quinine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine 400 mg per day
Study: 7488449
Drug: Vasodilator drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasodilator drug treatment for 12 weeks
Study: 21848526
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of glutamate
Study: 21848526
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (isotonic saline injection)
Study: 9879698
Drug: IgM antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgM antibodies reacting with the terminal disaccharide of galactose (beta1‐3)N‐acetylgalactosamine
Study: 23930866
Drug: Ketamine 1
Normalized name: ketamine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 1 mg/kg
Study: 2700773
Drug: 1‐mg dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1‐mg dexamethasone suppression test (DST)
Study: 24561125
Drug: Liraglutide 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.8 mg once daily
Study: 23278906
Drug: Group H:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group H: 1 ml·kg(‐1) of 0.25% ropivacaine injected after needle pierced the sacrococcygeal ligament under ultrasound guidance
Study: 9290118
Drug: Beta-carotene supplementation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene supplementation at 30 mg/day
Study: 3602015
Drug: Atenolol/diuretic (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol/diuretic (5 mg amiloride plus 50 mg hydrochlorothiazide once daily)
Study: 3602015
Drug: Atenolol/nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol/nifedipine (20 mg nifedipine twice daily)
Study: 12392115
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (normal daily activities)
Study: 31150502
Drug: Antidepressants and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants and Oxytocin
Study: 23601522
Drug: Routine medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medicine treatment (Group 2)
Study: 23601522
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Non-intervention group)
Study: 10349922
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml lidocaine 1.5% plus 15 microg epinephrine (1:200,000) i.v. at sevoflurane 0.5%
Study: 10349922
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml lidocaine 1.5% plus 15 microg epinephrine (1:200,000) i.v. at sevoflurane 1%
Study: 10349922
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml lidocaine 1.5% plus 15 microg epinephrine (1:200,000) i.v. at sevoflurane 2%
Study: 10349922
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml normal saline at sevoflurane 0.5%
Study: 10349922
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml lidocaine 1.5% plus 15 microg epinephrine (1:200,000) i.v. (all concentrations)
Study: 10349922
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml normal saline (all concentrations)
Study: 1672878
Drug: Levocabastine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocabastine (0.5 mg/ml)
Study: 1685691
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (20 mg/ml)
Study: 28078825
Drug: Ethanol 70%
Normalized name: Ethanol 70% Topical application Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 70% + unfractionated heparin 2000 U/mL
Study: 14988279
Drug: Transdermal 17‐beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17‐beta‐estradiol
Study: 9562227
Drug: Water (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (250 ml)
Study: 30606259
Drug: Combined criteria
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined criteria of total CTC count ≥10/5 mL and proportion of mesenchymal CTCs >10.7%
Study: 29445928
Drug: Lapatinib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib and trastuzumab (6 weeks) followed by lapatinib and trastuzumab plus weekly paclitaxel (12 weeks) with prolonged anti-HER2 therapy (18 weeks)
Study: 29445928
Drug: Lapatinib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib and trastuzumab (6 weeks) followed by lapatinib and trastuzumab plus weekly paclitaxel (12 weeks) with standard anti-HER2 therapy (6 weeks)
Study: 29445928
Drug: Lapatinib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib and trastuzumab (6 weeks) followed by lapatinib and trastuzumab plus weekly paclitaxel (12 weeks) with endocrine therapy
Study: 29445928
Drug: Lapatinib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib and trastuzumab (6 weeks) followed by lapatinib and trastuzumab plus weekly paclitaxel (12 weeks) without endocrine therapy
Study: 29445928
Drug: Prolonged anti-HER2
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Prolonged anti-HER2 therapy
Study: 27567886
Drug: Rotigotine ≤8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine ≤8 mg/24 h for early PD (HY 1 and 2)
Study: 26334249
Drug: Full-dose TIV
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose TIV (0.5 mL)
Study: 26334249
Drug: Half-dose TIV
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose TIV (0.25 mL)
Study: 20497416
Drug: tolterodine-ER +
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolterodine-ER + α-blocker
Study: 12688447
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of caffeine
Study: 25147328
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg/d (in subgroup with diabetes mellitus)
Study: 22251025
Drug: Quality improvement
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quality improvement (QI) intervention designed to improve access to antidepressant medications and/or cognitive behavior therapy
Study: 11738120
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D(3) infusions
Study: 2471025
Drug: Inosine-pranobex (INPX)
Normalized name: inosine pranobex
DrugBank: Inosine pranobex (DB13156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inosine-pranobex (INPX) 1000 mg every 6 hours for 3 months
Study: 169536
Drug: ACTH 4-10
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH 4-10 (30 mg/s.c.)
Study: 31069442
Drug: Baseline 25OHD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline 25OHD ≥ 50 nmol/L
Study: 24158313
Drug: Early removal
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early removal group (chest tube removal at drainage volume of 300 ml/24 h or less)
Study: 24158313
Drug: Traditional management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional management group (chest tube removal when drainage volume is less than 100 ml/24 h)
Study: 15959612
Drug: Cisapride (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (30 mg/day)
Study: 15959612
Drug: Bethanechol combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bethanechol combined with cisapride (30 mg/day each)
Study: 12642049
Drug: Interferon alfa-2a
Normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa-2a (10 million units/m2, daily for 7 days)
Study: 10757556
Drug: Amifostine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (1000 mg absolute)
Study: 3904977
Drug: Specific Immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific Immunotherapy Group - three monthly doses of 500 micrograms of tumor associated antigen (TAA) emulsified with complete Freund's adjuvant (CFA)
Study: 3904977
Drug: Nonspecific Immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonspecific Immunotherapy Group - three monthly doses of CFA emulsified in saline
Study: 3904977
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group - no treatment postoperatively
Study: 28990437
Drug: Overall patient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall patient acceptance of injection pain
Study: 20056354
Drug: Dose difference
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose difference map in bladder neck (trigonal region)
Study: 11940375
Drug: DHEAS (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEAS (100 mg q.d.) for 6 months
Study: 8571309
Drug: DIC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIC treatment
Study: 2407959
Drug: Warfarin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin and Aspirin (active treatment arms)
Study: 27171136
Drug: Pentoxifylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (400 mg daily)
Study: 25588369
Drug: Moro juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moro juice extract (Morosil(®), 400 mg/die)
Study: 22106341
Drug: GH replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH replacement therapy (0.24 mg/day in elderly, 0.33 mg/day in younger)
Study: 9329355
Drug: GH replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH replacement therapy
Study: 19843623
Drug: Atorvastatin (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (Group I) for 15 days prior to surgery
Study: 19843623
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group II) with no antihyperlipidemic agents
Study: 15271972
Drug: Two-implant ball
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-implant ball attachment group
Study: 19807860
Drug: Well-being therapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Well-being therapy
Study: 14602757
Drug: Immediate-release glipizide
Normalized name: glipizide Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release glipizide
Study: 7882817
Drug: Glipizide-GITS (controlled-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide-GITS (controlled-release glipizide)
Study: 24961363
Drug: Contingency management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingency management (CM) targeting psycho-stimulants
Study: 21735527
Drug: Provisional stenting
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provisional stenting with drug-eluting stents (DES) in group OR (stenosis < 50% of SB lumen area)
Study: 1720370
Drug: Low-dose bleomycin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose bleomycin (60 units)
Study: 2684006
Drug: Tetracycline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline (1 g)
Study: 24917661
Drug: Multidose metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multidose metronidazole (500 mg twice daily for 7 days)
Study: 30601374
Drug: Single-dose metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose metronidazole (2 g single-dose)
Study: 23891275
Drug: Pioglitazone 30mg
Normalized name: GLIMEPIRIDE 2MG/PIOGLITAZONE 30MG TAB
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone 30mg daily
Study: 29256535
Drug: Gemfibrozil 600mg
Normalized name: GEMFIBROZIL 600MG TAB
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemfibrozil 600mg daily